Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Q1 2022 Earnings Presentation
21 slides from Marinomed Biotech's earnings presentation, May 23, 2022
Slide 1: Investor Presentation Q1 2022
Investor Presentation Q1 2022 Andreas Grassauer, CEO, Pascal Schmidt, CFO Frankfurt, 23rd May 2022
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Financials Q1 2022 Pascal Schmidt, CFO • Strategic horizons for Marinomed Andreas Grassauer, CEO • Update on key projects • Investment highlights & outlook • Financial calendar, contact © Marinomed Biotech AG 3
Slide 4: Highlights to date
Highlights to date Delivering on our promises January – Strengthening business development through new CBO Cornelia Kutzer February – Draw down of €6m EIB financing tranche – meeting all predefined milestones April – New agreement with Hanmi for marketing of Carragelose in South Korea April – Strong
Slide 5: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Financials Q1 2022 Pascal Schmidt, CFO • Strategic horizons for Marinomed Andreas Grassauer, CEO • Update on key projects • Investment highlights & outlook • Financial calendar, contact © Marinomed Biotech AG 5
Slide 6: Continuous double digit growth
Continuous double digit growth Strong Carragelose business with upfront from first Marinosolv-deal Y-o-Y comparison of quarterly revenues (m€) Comments Key growth drivers 5.9* • Sale of goods rose from €2.1m to €2.2m 3.1 2.8 2.5 2.2 2.4 • Solv4U generated other revenues 1.3 1.0 New business Q2 Q2 Q3
Slide 7: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) Higher revenues – improved EBIT €m Q1 2022 Q1 2021 1 Q1 2022 Q1 2021 Sale of goods 2.2 2.1 Revenues 1 2.4 2.2 Milestones 0.0 0.0 Other income 2 0.1 0.5 License revenues 0.1 0.1 Materials expenses Other revenues 0.1 0.0 -1.5 -1.4 Total revenues 2.4 2.2 Services expe
Slide 8: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m Q1 2022 FY 2021 •1 Includes fully recognized headquarter, incl. land and building (€5.6m) therein directly R&D related* (€0.5m) Assets Intangible assets 2.0 2.0 2 Inventories €m Q1 2022 FY 2021 Property, plant and equipment Goods for sale 0.2 0.1 1 6.
Slide 9: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m Q1 2022 FY 2021 •1 Capital increases through convertible note funding program Equity and liabilities Share capital 1.5 1.5 •2 Primarily related to EIB loan (€15.0m) and ERP/aws and NÖBEG real estate refinancing (€4.8m) Capital reserves
Slide 10: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Financials Q1 2022 Pascal Schmidt, CFO • Strategic horizons for Marinomed Andreas Grassauer, CEO • Update on key projects • Investment highlights & outlook • Financial calendar, contact © Marinomed Biotech AG 10
Slide 11: Strategic horizons for Marinomed
Strategic horizons for Marinomed Long-term vision Strategy 2025f Leading biopharma company for rare autoreactive immune disorders and Move towards higher valued viral infectious diseases Rx drugs addressing unmet Short-term medical needs Maximise current OTC portfolio Succeed with next-generation
Slide 12: Strong pipeline – still more to come
Strong pipeline – still more to come Growth potential to pursue Solid base to build on © Marinomed Biotech AG 12
Slide 13: Fighting against visual impact
Fighting against visual impact Rare disease herpetic stromal keratitis caused by ocular herpes virus infection Prevalence Unmet medical need Herpesvirus induced keratitis • >90% of the global population has a latent In the developed world without China infection with HSV-1 by the age of sixty1 Epith
Slide 14: Tacrolimus
Tacrolimus Best in class macrolide immunosuppressant –a substance that could benefit so many more patients when solubilized • Macrolide calcineurin inhibitor Tacrosolv is a Marinosolv-enabled formulation of Tacrolimus in an aqueous solution1 • Practically insoluble in water Bioavailability is strong
Slide 15: Tacrosolv
Tacrosolv Fully solubilized macrolide immunosuppressant – validated in clinical phase II trial TOSS* day 8 % reduction compared to day 1 Rationale for the use of Tacrosolv 6 • Clinical proof of concept in the model Placebo Verum 5 0 indication allergic conjunctivitis showing an anti-inflammatory act
Slide 16: Timeline 2022/2023
Timeline 2022/2023 News flow / milestones • January – Strengthening business development through new CBO Cornelia Kutzer • February – Draw down of €6m EIB financing tranche News flow to • April – New agreement with Hanmi for marketing of Carragelose in South Korea date • April – Publication of stron
Slide 17: Sustainability
Sustainability Marinomed contributes to sustainability goals and adheres to ESG • Develop products containing less API – for patients and for the environment • Use more renewable energy • Promote environmentally friendly supply chains ENVIRONMENT • Therapies for people living with diseases with limi
Slide 18: The Marinomed story
The Marinomed story Transforming lives of people living with diseases with limited or no treatment options • Highly experienced management • Short term and long-term growth perspective • Therapies for diseases with unmet medical need • Lean and efficient business model • Sustainable therapies © Mari
Slide 19: Agenda
Agenda • Highlights Q1 2022 Andreas Grassauer, CEO • Financials Q1 2022 Pascal Schmidt, CFO • Strategic horizons for Marinomed Andreas Grassauer, CEO • Update on key projects • Investment highlights & outlook • Financial calendar, contact © Marinomed Biotech AG 19
Slide 20: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar Stephanie Kniep June 5, 2022 Record date AGM Investor Relations phone: +43 2262 90300 226 June 15, 2022 AGM e-mail: IR@marinomed.com August 25, 2022 Publication of the Results H1 2022 November 21, 2022 Publication of the Results Q1-Q3 2022 © Marinom
Slide 21: Thank you!
Thank you! © Marinomed Biotech AG 21